Randomised Evaluation of COVID-19 Therapy (RECOVERY)
Site and study lead:
- Manchester Royal Infirmary: Prof Simon Carley
- Wythenshawe Hospital: Dr Tim Felton
- Royal Manchester Children’s Hospital: Dr Claire Murray
Patient group: all COVID-19 patients
- Convalscent Plasm
- *Tocilizumab (secondary randomisation arm)
Funder: Medical Research Council
Sponsor: University of Oxford
More about RECOVERY
- RECOVERY is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.
- Read more about RECOVERY at MFT in our website news story.
- Read more about MFT’s role in the RECOVERY trial here.
The purpose of this trial is to test if existing or new drugs can help patients hospitalised with confirmed COVID-19.
The therapies being tested will be evaluated to see if they are safe and effective when added to the usual standard of care.
RECOVERY has an ‘adaptive’ design, meaning it can test new therapies as they become available. The aim is for national data to be available to inform patient treatment within three months.